

References

1. Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. *Neurology*. 2005;65:33-39.
2. Francis GS, Rice G, Alsop JC, et al. Interferon β -1a in MS: Results following development of neutralizing antibodies in PRISMS. *Neurology*. 2005;65:48-55.
3. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. *Neurology*. 2002;59:679-687.
4. Natalizumab [prescribing information]. Cambridge, MA: Biogen Idec Inc; 2008. Available at: <http://www.tysabri.com>. Accessed December 16, 2008.
5. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med*. 2003;348:15-23.
6. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. *Lancet*. 2002;360:2018-2025.
7. Mitoxantrone for injection concentrate [prescribing information]. Rockland, MA: Serono, Inc; 2008. Available at: http://www.novantrone.com/assets/pdf/novantrone_prescribing_info.pdf. Accessed December 16, 2008.
8. Ghalie RG, Mauch E, Edan G, et al. A study of therapy related acute leukaemia after mitoxantrone therapy for multiple sclerosis. *Mult Scler*. 2002;8:441-445.
9. Ledda A, Caocci G, Spinicci G, et al. Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis. *Leukemia*. 2006;20:2217-2218.
10. Bosca I, Pascual AM, Casanova B, et al. Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone. *Neurology*. 2008;71:457-458.
11. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. *Ann Neurol*. 2007;61:14-24.
12. Fazekas F, Lublin FD, Li D, et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. *Neurology*. 2008;71:265-271.
13. Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. *Lancet*. 2004;364:1149-1156.

14. Goodkin DE, Kinkel RP, Weinstock-Guttman B, et al. A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. *Neurology*. 1998;51:239-245.